Horm Metab Res 2003; 35(11/12): 664-666
DOI: 10.1055/s-2004-814165
Review
© Georg Thieme Verlag Stuttgart · New York

The Role of the GH/IGF System in Pituitary Tumorigenesis

W.  Zumkeller1
  • 1Department of Paediatrics, Johann Wolfgang Goethe-University, Frankfurt, Germany
Weitere Informationen

Publikationsverlauf

Received 31 August 2003

Accepted without Revision 17 September 2003

Publikationsdatum:
07. Januar 2004 (online)

Zoom Image

Abstract

Pituitary adenomas are mostly benign tumours that originate from differentiated anterior pituitary cells. Altered expression of growth factors or their receptors could enhance clonal expansion of pituitary adenoma cells. GHRH overstimulation or an activating point mutation in the Gsa-subunit leads to increased GH secretion and tumour formation. In contrast, IGF-I suppresses basal and GHRH-stimulated GH secretion in pituitary adenoma cells, whereas prolactin secretion is unaffected. Somatostatin analogues and pegvisomant, a novel growth hormone-receptor antagonist, results in a reduction of serum IGF-I levels and clinical improvement in patients suffering from pituitary adenoma. Thus, this review focuses on the role of the growth hormone/insulin-like growth factor system in pituitary tumorigenesis with particular focus on the genetic alterations described in pituitary adenomas up to now.